UNSPSC 51171807: Cinnarizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H28N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DI2E1X18L, chemically known as piperazine, 1- (diphenylmethyl)-4-(3-phenyl-2-propenyl)-, (e)- but generally known as cinnarizine, which bears US NIH Compound Identifier 2761. European Medicines Agency schedules Cinnarizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06302MIG.

UNSPSC 51171807 Cinnarizine, a Commodity code, represents pharmaceutical products and services that state and local governments procure for correctional health programs, pharmacy benefit management, and multistate cooperative purchasing networks. The recent opportunities under this code span offender drug testing with pharmaceutical screening and confirmation protocols, state-level pharmacy benefit initiatives exploring direct manufacturer relationships, and multistate generic pharmaceutical supply agreements. State and local issuing bodies soliciting under the code include county correction departments, state health and human services commissions, and multistate cooperative purchasing alliances; Collin County Community Supervision and Corrections Department and the Texas Health and Human Services Commission appear as active procurers in the current cycle. The scope of work encompasses laboratory-based drug screening and confirmation testing (immunoassay and LC/MS/MS or GC/MS confirmation), alternative testing methodologies including oral fluid and hair analysis, pharmacy benefit program administration and direct manufacturer contracting capabilities, and generic pharmaceutical supply fulfillment through authorized wholesaler networks with compliance to cGMP and DSCSA standards.

Recent activity concentrates in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services on July 9, 2026, with proposals due July 23, 2026, comprising approximately 25,031 annual tests across five-panel and six-panel screening with confirmation testing, two collection sites in Plano and McKinney, and an estimated contract value of $600,000 over two years with three optional one-year renewal periods. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for establishing relationships between the state pharmacy benefit program and pharmaceutical manufacturers outside of existing pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing alliance, issued RFP S1070000015802 on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon through three authorized wholesalers, with products required available in the marketplace by May 15, 2026, and resulting agreements effective July 1, 2026.